Lilly Sets Up First China Venture Fund
This article was originally published in PharmAsia News
After its initial investment in BioVeda China, Eli Lilly Asia Capital Fund is set to enter the second phase of directly investing in the pharmaceutical sector. According to officials, the fund, which targets China as a major investment market, is focusing on life sciences, medical and diagnostic devices, and health care. Project collaboration with universities and academic institutions in key coastal cities will get an initial injection of $1-5 million and up to a total of $10-15 million each. GSK is considering setting up its own venture capital in China if suitable projects are available. (Click here for more - Chinese Language)
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.